HP
SCLN

HealthInvest Partners’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

HealthInvest Partners’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-236,288
Closed -$2.6M – 21
2016
Q1 		$2.6M Buy
+236,288
New +$2.1M 1.22% 17
2014
Q1 		– Sell
-135,000
Closed -$680K – 22
2013
Q4 		$680K Buy
+135,000
New +$650K 0.68% 16

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HealthInvest Partners's SCLN Position: Q2 2016 in Review

HealthInvest Partners sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2016, closing a stake of 236,288 shares — an estimated $2.6M sold.

HealthInvest Partners first reported a position in SCLN in Q4 2013 and held it in 2 quarters. The position peaked at $2.6M in Q1 2016. 151 funds tracked by Wall St. Rank hold SCLN as of Q2 2016.

  • HealthInvest Partners reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • HealthInvest Partners sold 236,288 Sciclone Pharmaceuticals Inc shares in Q2 2016, an estimated $2.6M.
  • HealthInvest Partners first reported a position in Sciclone Pharmaceuticals Inc in Q4 2013 and held it in 2 quarters.
  • HealthInvest Partners's Sciclone Pharmaceuticals Inc position peaked at $2.6M in Q1 2016.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2016.

Based on HealthInvest Partners's 13F filing for Q2 2016, filed 26 Jul 2016.